Article Per Year (5 Year)
p-Index From 2021 - 2026
0.444
P-Index
This Author published in this journals
All Journal Journal of the Medical Sciences (Berkala Ilmu Kedokteran) Indonesian Journal of Cardiology ACI (Acta Cardiologia Indonesiana)
Krisdinarti, Lucia
Cardiology And Vascular Educational Program, Faculty Of Medicine / Dr. Sardjito General Hospital, Universitas Gadjah Mada, Yogyakarta
Health Professions Immunology & microbiology Medicine & Pharmacology Neuroscience

Published : 11 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 11 Documents
Search

 1   2 
Pulmonary vascular resistance/systemic vascular resistance (PVR/SVR) ratio changes after sildenafil therapy in uncorrected congenital heart disease-associated pulmonary arterial hypertension Evita Devi Noor Rahmawati; Putrika Prastuti Ratna Gharini; Anggoro Budi Hartopo; Lucia Kris Dinarti; Dyah Wulan Anggrahini
Journal of the Medical Sciences (Berkala Ilmu Kedokteran) Vol 55, No 1 (2023)
Publisher : Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.19106/JMedSci005501202305

Abstract

Pulmonary vascular resistance (PVR) to systemic vascular resistance (SVR) ratio is a prognostic predictor in congenital heart disease (CHD)-associated pulmonary arterial hypertension (PAH) after defect correction. Sildenafil, widely used as a PAH drug, can decrease PVR with minimal or without changes in SVR, resulting in decreased PVR/SVR ratio after treatment. However, there is limited evidence that PVR/SVR ratio reduced after sildenafil therapy in uncorrected CHD-associated PAH patients. This study aimed to investigate the decreasing of the PVR/SVR ratio after ≥ 1-year oral sildenafil therapy in adult uncorrected CHD-associated PAH. A total of 30 uncorrectable CHD-associated PAH subjects derived from the COHARD-PH registry were included in this study. Right heart catheterization (RHC) was performed during the first visit and further evaluations were conducted after ≥1-year oral sildenafil therapy. The PVR/SVR ratio at the baseline and after the evaluation was collected. The primary outcome of this study was the changes in PVR/SVR ratio from baseline to evaluated RHC. Characteristic analysis of subjects with decreased PVR or PVR/SVR ratio was perforemd as the secondary outcome. The mean PVR and SVR were not different from baseline and evaluated RHC (15.98± 10.67 vs. 18.38±13.93 WU, p=0.206 and 36.65±13.99 vs. 39.34±15.46 WU, p=0.262). There was no significant difference in the baseline PVR/SVR ratio and the evaluated PVR/SVR ratio after ≥1-year sildenafil therapy (0.48 ±0.32 vs. 0.49±0.36; p=0.882). As much as 15 subjects (50%) experienced decreased PVR/SVR ratio. However, there was no significant difference in the characteristics, including age, Eisenmenger syndrome, type of shunts, baseline PVR, PAH-specific treatment, and baseline NT-proBNP level (p>0.05). In conclusion, sildenafil therapy does not change PVR/SVR ratio in adults with uncorrected CHD-associated PAH.
Co-Authors Abdul Majid Halim Wiradhika Anggoro Budi Hartopo Anggoro Budi Hartopo Anggoro Budi Hartopo Anggoro Budi Hartopo Azhafid Nashar Bambang Budi Siswanto Bambang Irawan Basuki Rahmat Braghmandaru Adhi Bhaskara Budi Yuli Setianto Citra Dewi Wahyu Fitria Dyah Wulan Anggrahini Erika Maharani Evita Devi Noor Rahmawati Firandi Saputra Gharini, Putrika Prastuti Ratna Hafizha Herman Hariadi Hariawan Hasanah Mumpuni Hendry Purnasidha Bagaswoto Indra Widya Nugraha Irmalita I Muhammad Reyhan Hadwiono Putrika PR Gharini Rano Irmawan Vera Dewanto